Page last updated: 2024-12-11

igmesine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID6438340
CHEMBL ID2110660
SCHEMBL ID195583
SCHEMBL ID5564392
MeSH IDM0179631

Synonyms (14)

Synonym
unii-xa3745j38k
igmesine [inn]
140850-73-3
xa3745j38k ,
(+)-alpha-((e)-cinnamyl)-n-(cyclopropylmethyl)-alpha-ethyl-n-methylbenzylamine.
igmesine
(e)-n-(cyclopropylmethyl)-n-methyl-3,6-diphenylhex-5-en-3-amine
CHEMBL2110660
(+)-n-(cyclopropylmethyl)-alpha-ethyl-n-methyl-alpha-[(2e)-3-phenyl-2-propen-1-yl]benzenemethanamine
benzenemethanamine, n-(cyclopropylmethyl)-alpha-ethyl-n-methyl-alpha-[(2e)-3-phenyl-2-propen-1-yl]-, (+)-
SCHEMBL195583
SCHEMBL5564392
Q5992117
DTXSID801028764

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" This potentiation is dose-dependent at doses between 1 and 1000 micrograms/kg, IV but bell-shaped dose-response curves are obtained."( Effects of low and high doses of selective sigma ligands: further evidence suggesting the existence of different subtypes of sigma receptors.
Bergeron, R; Debonnel, G, 1997
)
0.3
" We have shown that sigma ligands, such as di(2-tolyl)guanidin (DTG), potentiate dose-dependently, with bell-shaped dose-response curves, the neuronal response of pyramidal neurones to N-methyl-D-aspartate (NMDA) in the CA3 region of the rat dorsal hippocampus."( Effect of short-term and long-term treatments with sigma ligands on the N-methyl-D-aspartate response in the CA3 region of the rat dorsal hippocampus.
Bergeron, R; de Montigny, C; Debonnel, G, 1997
)
0.3
" Moreover, they support the notion of a bell-shaped dose-response curve previously reported for sigma ligands."( Effects of sigma ligands on NMDA receptor function in the bulbectomy model of depression: a behavioural study in the rat.
Bermack, J; Debonnel, G; Dryver, E; Lavoie, N, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (53)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's32 (60.38)18.2507
2000's18 (33.96)29.6817
2010's3 (5.66)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.79%)5.53%
Reviews4 (7.14%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other51 (91.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]